Difference between revisions of "MitoKit-CII"
From Bioblast
Beno Marija (talk | contribs) |
Beno Marija (talk | contribs) |
||
| Line 6: | Line 6: | ||
|product image= | |product image= | ||
}} | }} | ||
__TOC__ | __TOC__ | ||
== Compounds of MitoKit-CII == | |||
:::: The MitoKit-CII consists of the first generation of NeuroVive Pharmaceutical AB's cell permeable succinate and malonate prodrugs. It was developed to stimulate (succinate) or inhibit (malonate) the Complex II of the respiratory electron transfer system in intact cells, and will expand the toolbox for evaluating the role of mitochondria in disease. | |||
:::: The MitoKit-CII is composed of the following compounds: | :::: The MitoKit-CII is composed of the following compounds: | ||
| Line 26: | Line 26: | ||
::::: Aliquots of 10 mg | ::::: Aliquots of 10 mg | ||
::::* For preparation, see [[MitoKit-CII MitoPedia]]. | |||
::::* Reference: | ::::* Reference: | ||
:::::: Ehinger JK, Piel S, Ford R, Karlsson M, Sjövall F, Frostner EÅ, Morota S, Taylor RW, Turnbull DM, Cornell C, Moss SJ, Metzsch C, Hansson MJ, Fliri H, Elmér E (2016) Cell-permeable succinate prodrugs bypass mitochondrial Complex I deficiency. Nat Commun 7:12317. [[Ehinger 2016 Nat Commun|»Bioblast link«]] - Original publication introducing Mito-CII. | :::::: Ehinger JK, Piel S, Ford R, Karlsson M, Sjövall F, Frostner EÅ, Morota S, Taylor RW, Turnbull DM, Cornell C, Moss SJ, Metzsch C, Hansson MJ, Fliri H, Elmér E (2016) Cell-permeable succinate prodrugs bypass mitochondrial Complex I deficiency. Nat Commun 7:12317. [[Ehinger 2016 Nat Commun|»Bioblast link«]] - Original publication introducing Mito-CII. | ||
Revision as of 17:14, 28 March 2019
MitoKit-CII
| Description | Cell permeable compound - MitoKit-CII, 2 vials; 1 vial of NV118 (25 mg) + 1 vial of NV161 (10 mg) |
|---|---|
| Product ID | 60200-01 |
| Type | O2k |
| Link | MitoKit-CII MitoPedia |
| Image |
Compounds of MitoKit-CII
- The MitoKit-CII consists of the first generation of NeuroVive Pharmaceutical AB's cell permeable succinate and malonate prodrugs. It was developed to stimulate (succinate) or inhibit (malonate) the Complex II of the respiratory electron transfer system in intact cells, and will expand the toolbox for evaluating the role of mitochondria in disease.
- The MitoKit-CII is composed of the following compounds:
- Cell permeable compound NV118/MitoKit-CII
- Description: Succinate prodrug: C10H14O8, Molecular weight 262,2g.mol-1
- Aliquots of 25 mg
- Cell permeable compound NV161/MitoKit-CII
- Description: Malonate prodrug: C9H12O8, Molecular weight 248,2g.mol-1
- Aliquots of 10 mg
- For preparation, see MitoKit-CII MitoPedia.
- Reference:
- Ehinger JK, Piel S, Ford R, Karlsson M, Sjövall F, Frostner EÅ, Morota S, Taylor RW, Turnbull DM, Cornell C, Moss SJ, Metzsch C, Hansson MJ, Fliri H, Elmér E (2016) Cell-permeable succinate prodrugs bypass mitochondrial Complex I deficiency. Nat Commun 7:12317. »Bioblast link« - Original publication introducing Mito-CII.
Expiry date of MitoKit-CII compounds (according to NeuroVive)
Before preparation:
- 3 years in -80° C
- 1 year in -20° C
Prepared:
- In DMSO solution
- at room temperature: 24 hours
- at -20 °C: for weeks
CAS-Numbers:
- NV118/MitoKit-CII: 1592635-33-0
- NV161/MitoKit-CII: 1432752-62-9
Labels: MiParea: Instruments;methods
HRR: O2k-Protocol
O2k-chemicals and media
